UroGen Pharma (URGN) Tops Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Birkenstock surges on revenue beat, higher full-year outlook
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
UroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate Developments
August 10, 2020 8:00 AM EDTReceived U.S. FDA Approval of Jelmyto®, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)
Successfully Commenced Launch of Jelmyto on June 1st as Planned; Initial Commercial Performance Demonstrates Strong Execution
Announced Positive Complete Response and Durability Data of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC); On Track to Commence Pivotal Phase 3 Trial by Year End
Conference Call and Webcast to be Held Today at 8:30 AM ET
... More
